article thumbnail

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera , as well as plans to continue the relationship into Phase III.

article thumbnail

Unveiling the threat of crystalline silica on the cardiovascular system. A comprehensive review of the current knowledge

Frontiers in Cardiovascular Medicine

Specific cardiovascular diseases, such as acute myocardial infarction, arrhythmias, pulmonary hypertension and pericarditis, were also pointed. SiO2 exposure was linked to an increased risk of myocardial infarction, with potential mechanisms involving inflammation and platelet activation.

article thumbnail

Inflammation as the nexus: exploring the link between acute myocardial infarction and chronic obstructive pulmonary disease

Frontiers in Cardiovascular Medicine

Chronic obstructive pulmonary disease (COPD), particularly following acute exacerbations (AE-COPD), significantly heightens the risks and mortality associated with acute myocardial infarction (AMI).

article thumbnail

Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment

The New England Journal of Medicine

A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin–angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an (..)

article thumbnail

Aspiration of thrombus for intermediate-risk subacute pulmonary embolism

Journal of Cardiothoracic Surgery

Pulmonary embolism is the most common cardiovascular disease after myocardial infarction and stroke. Konstantinides (Eur Heart J 41(4):543–603, 2020) Current guidelines categorize patients with PE as being at.

article thumbnail

EFFECTS OF PTEROSTILBENE ON HEART AND LUNG OXIDATIVE STRESS PARAMETERS IN TWO EXPERIMENTAL MODELS OF CARDIOVASCULAR DISEASE: MYOCARDIAL INFARCTION AND PULMONARY ARTERIAL HYPERTENSION

Journal of Cardiovascular Pharmacology

Myocardial infarction (MI) and pulmonary artery hypertension (PAH) are two prevalent cardiovascular diseases. This study aims to evaluate the effect of PTE on oxidative stress in the hearts of animals with myocardial infarction and in the lungs of animals with PAH. Male Wistar rats were used in both models.

article thumbnail

Abstract 4135252: Associations between Group 2 Pulmonary Hypertension and 30-Day Readmissions Following Acute Myocardial Infarction Hospitalizations.

Circulation

Background:Pulmonary hypertension (PH) is a major contributor to cardiovascular disease-related morbidity and mortality.